JPRN-jRCT2080223576已完成3 期
Phase III comparative study of KRP-108 -Open-label, active-controlled, crossover comparative study of KRP-108 in pediatric bronchial asthma
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 87
研究概览
简要总结
The non-inferiority of KRP-108 to SFC was verified in terms of the primary endpoint, mPEF and there were no significant safety issues with KRP-108.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 5age old 至 <= 15age old（—）
- 性别
- All
入选标准
- •Known history of bronchial asthma for 12 > weeks.
排除标准
- •Complication of chronic pulmonary disease without bronchial asthma and diseases affecting respiratory function.
- •Complication of hypokalemia.
研究者
相似试验
未知
3 期
KRP-108 comparative studyAsthmaJPRN-jRCT2080221303Kyorin Pharmaceutical Co.,LTD
已完成
1 期
A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy VolunteersHealthyNCT01637285Pfizer49
已完成
3 期
ong-term study of KRP-108Bronchial asthmaJPRN-jRCT2080223577Kyorin Pharmaceutical Co.,LTD53
已完成
3 期
A Phase III, comparative study of KRP-AM1977Y in community- acquired pneumoniaJPRN-jRCT2080223246Kyorin Pharmaceutical Co.,LTD286
已完成
1 期
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFSPolyarticular Juvenile Idiopathic ArthritisRheumatoid ArthritisPediatric Plaque PsoriasisPediatric Crohns DiseaseNon-infectious UveitisUlcerative ColitisCrohn DiseasePsoriatic ArthritisAnkylosing SpondylitisHidradenitis SuppurativaPlaque PsoriasisNCT04018599Fresenius Kabi SwissBioSim GmbH216